Q2 2026 saw strong revenue and profit growth, record product sales, and robust cash flow. Key products Buvidal and Brixadi delivered double-digit growth, while pipeline and commercial expansion remain top priorities. Regulatory and capacity risks are being actively managed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.